• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sera Prognostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/4/26 5:13:10 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    8-K
    false000153496900015349692026-06-042026-06-04

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 04, 2026

     

     

    Sera Prognostics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40606

    26-1911522

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2749 East Parleys Way

    Suite 200

     

    Salt Lake City, Utah

     

    84109

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (801) 990-0520

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A Common Stock, $0.0001 par value per share

     

    SERA

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On June 4, 2026, Sera Prognostics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 38,190,966 shares of Class A common stock, par value $0.0001 per share, issued and outstanding and eligible to vote as of the record date of April 13, 2026, a quorum of 25,773,203 shares, or 67.5% of the eligible shares, was present at the meeting or represented by proxy.

    At the Annual Meeting, the stockholders: (1) elected each of Kim Kamdar, Ph.D. and Sandra A. J. Lawrence to the Company’s Board of Directors as a Class II director for a term of three years to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal (“Election of Directors”); and (2) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Auditor Ratification”). A more complete description of each of these matters is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 24, 2026.

    The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

    1. Election of Directors

    Nominee

     

    Shares Voted For

     

     

    Shares Voted to Withhold Authority

     

     

    Broker Non-votes

     

    Kim Kamdar, Ph.D.

     

     

    9,749,623

     

     

     

    3,062,352

     

     

     

    12,961,228

     

    Sandra A. J. Lawrence

     

     

    12,483,966

     

     

     

    328,009

     

     

     

    12,961,228

     

    2. Auditor Ratification

    Shares Voted For

     

    Shares Voted Against

     

    Shares Abstaining

     

    Broker Non-votes

    24,917,046

     

    856,113

     

    44

     

    —

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SERA PROGNOSTICS, INC.

     

     

     

     

    Date:

    June 4, 2026

    By:

    /s/ Austin Aerts

     

     

     

    Austin Aerts
    Chief Financial Officer

     


    Get the next $SERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    6/4/2026$6.00Buy
    Craig Hallum
    12/15/2025$5.00Buy
    Jefferies
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

    SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Comp

    6/1/26 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

    SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    4/22/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

    SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key 2025 and Recent Highlights:Data Generation Published Landmark PRIME Study Demonstrating PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications: In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women,

    3/18/26 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Sera Prognostics with a new price target

    Craig Hallum initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $6.00

    6/4/26 7:57:28 AM ET
    $SERA
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Sera Prognostics with a new price target

    Jefferies initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $5.00

    12/15/25 10:01:13 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics downgraded by Citigroup with a new price target

    Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

    3/30/22 7:52:32 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    SEC Filings

    View All

    Sera Prognostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    6/4/26 5:13:10 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Sera Prognostics Inc.

    DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    6/1/26 4:46:27 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    6/1/26 4:44:21 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Elliott Jeffrey Thomas

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    6/4/26 4:16:56 PM ET
    $SERA
    Medical Specialities
    Health Care

    General Counsel Jackson Benjamin was granted 5,000 shares, increasing direct ownership by 3% to 163,935 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    6/1/26 4:49:50 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Commercial Officer Anderson Dyaarl Lee Jr. was granted 3,168 shares, increasing direct ownership by 4% to 82,737 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    6/1/26 4:49:25 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    View All

    SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

    SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Comp

    6/1/26 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

    SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns. Dr. Inglis joins Se

    10/1/25 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Sera Prognostics Inc.

    SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/1/24 7:33:43 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

    SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    4/22/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

    SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    3/4/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, while engaging with multiple payers across thirteen states, collectively representing a significant

    11/13/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care